August 15, 2024 – Durham, NC

MAA Laboratories is pleased to announce its acceptance into the FDA’s Emerging Technologies Program (ETP) for its cutting-edge NanoCont™ platform. Participation in the program opens a new avenue for communication with FDA experts, significantly benefiting the application of our proprietary drug delivery technology. The NanoCont™ platform, known for its nanoparticle approach and advanced manufacturing techniques, aligns with Quality by Design and Continuous Manufacturing principles. ETP membership facilitates early feedback, streamlined reviews, and regulatory clarity, enhancing our development strategy and market appeal. This is another indication of the value of NanoCont™ as an innovation in pharmaceutical technology.

For press and other inquiries, please contact:

Email: info@maalaboratories.com
Phone: 919.271.7868